Key result
Nitric oxide pathway drives PAH pathogenesis and offers potential therapeutic targets and non-invasive biomarkers.
Why the study?
This review summarizes current knowledge on the involvement of the nitric oxide pathway in the pathomechanism of PAH and explores novel biomarkers.
This review highlights the critical role of the NO pathway in PAH pathogenesis and the potential of NO-targeted therapies and biomarkers in disease management.
Answers are grounded in this paper and cite their sources.
Supports NO-targeted PAH therapies; leaves open prospective validation of proposed non-invasive biomarkers before clinical adoption.
The altered Nitric Oxide (NO) pathway in the pulmonary endothelium leads to increased vascular smooth muscle tone and vascular remodelling, and thus contributes to the development and progression of pulmonary arterial hypertension (PAH). The pulmonary NO signalling is abrogated by the decreased expression and dysfunction of the endothelial NO synthase (eNOS) and the accumulation of factors blocking eNOS functionality. The NO deficiency of the pulmonary vasculature can be assessed by detecting nitric oxide in the exhaled breath or measuring the degradation products of NO (nitrite, nitrate, S-nitrosothiol) in blood or urine. These non-invasive biomarkers might show the potential to correlate with changes in pulmonary haemodynamics and predict response to therapies. Current pharmacological therapies aim to stimulate pulmonary NO signalling by suppressing the degradation of NO (phosphodiesterase- 5 inhibitors) or increasing the formation of the endothelial cyclic guanosine monophosphate, which mediates the downstream effects of the pathway (soluble guanylate cyclase sensitizers). Recent data support that nitrite compounds and dietary supplements rich in nitrate might increase pulmonary NO availability and lessen vascular resistance. This review summarizes current knowledge on the involvement of the NO pathway in the pathomechanism of PAH, explores novel and easy-to-detect biomarkers of the pulmonary NO.
No takes yet. Share an insight, caveat, or question.
Lázár et al. (2020) conducted a review in Pulmonary Arterial Hypertension. Nitric Oxide pathway therapies and biomarkers was evaluated. The nitric oxide pathway plays a key role in the pathomechanism of pulmonary arterial hypertension, serving as a target for current therapies and offering potential non-invasive biomarkers.
Synapse has enriched 10 related papers. Consider them for comparative context: